FindTrial
Sign In

Expanded Access for KHK2455

Expanded Access for KHK2455

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04321694
Enrollment
Unknown
Registered
2020-03-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma Multiforme

Brief summary

This is an expanded access program for eligible participants. This program is designed to provide access to KHK2455 in combination with Mogamulizumab prior to the approval by the local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving this investigational therapy based on the individual patients medical history and eligibility criteria.

Interventions

DRUGKHK2455

Sponsors

University of New Mexico Cancer Center
CollaboratorOTHER
Kyowa Kirin, Inc.
Lead SponsorINDUSTRY

Eligibility

Inclusion criteria

\-

Exclusion criteria

\-

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026